Roche reveals the data that has it excited about giredestrant in early-stage breast cancer, but how might it be positioned versus CDK4/6 inhibitors?
GSK wins FDA approval for long-acting asthma drug
GSK secured FDA approval for an inflammatory disease drug that it says could reach £3 billion ($4 billion) in peak sales. The agency greenlit depemokimab

